polyphenol whole tumor cell vaccine

The polyphenol whole tumor cell vaccine is an investigational cancer immunotherapy that utilizes autologous or allogeneic tumor cells cloaked with a metallic polyphenol nanocoating. This coating is created by coordinating natural plant-derived polyphenols with manganese ions (Mn2+), forming a stable shell around the entire tumor cell. The surface of these coated cells is further modified with bacterial lipopolysaccharide (LPS) to enhance immune recognition and uptake by dendritic cells. Upon internalization, the coating releases manganese ions and preserved tumor antigens inside dendritic cells, activating the stimulator of interferon genes (STING) pathway and promoting robust maturation of dendritic cells. This leads to efficient presentation of a broad spectrum of native tumor antigens to T-cells, resulting in enhanced anti-tumor immune responses. Preclinical studies have shown significant inhibition of tumor growth in mouse models, especially when combined with immune checkpoint inhibitors such as anti-PD-L1 antibodies[2][3][4]. The approach aims to overcome limitations seen in traditional autologous whole-cell vaccines by preserving immunogenic neoantigens and providing strong adjuvant effects via STING activation[4]. The technology was published in Angewandte Chemie International Edition in 2024[2][4]. Primary indications under investigation are advanced malignant solid tumors including melanoma; clinical trials are ongoing[1][3].

Other names

metal-phenolic nanocloak whole-cell cancer vaccineMnTA nanocloak vaccine